BTIG analyst Mark Massaro maintained a Buy rating on Akoya Biosciences (AKYA – Research Report) yesterday and set a price target of $9.00. The company’s shares closed last Friday at $4.88.
According to TipRanks, Massaro is an analyst with an average return of -15.6% and a 33.00% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS.
Currently, the analyst consensus on Akoya Biosciences is a Strong Buy with an average price target of $9.00, representing an 84.43% upside. In a report released on December 19, Canaccord Genuity also maintained a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Akoya Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $25.22 million and a GAAP net loss of $12.92 million. In comparison, last year the company earned a revenue of $18.85 million and had a GAAP net loss of $17.87 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akoya Biosciences (AKYA) Company Description:
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
Read More on AKYA:
- Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
- Akoya Biosciences initiated with neutral view at Guggenheim, here’s why
- Akoya Biosciences price target lowered to $9 from $14 at Stephens
- Akoya Biosciences sees FY23 revenue $95M-98M, consensus $96.74M
- Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
